| Mantle cell lymphoma

Tecartus vs Revlimid

Side-by-side clinical, coverage, and cost comparison for mantle cell lymphoma.

Deep comparison between: Tecartus vs Revlimid with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsRevlimid has a higher rate of injection site reactions vs Tecartus based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Revlimid but not Tecartus, including UnitedHealthcare

Category

Tecartus

Revlimid

At A Glance

RouteIV infusion

FrequencySingle infusion

ClassCD19-directed CAR-T cell therapy

RouteOral

FrequencyDaily on Days 1-21 of repeated 28-day cycles

ClassImmunomodulatory agent targeting cereblon

Indications

Mantle cell lymphoma
Precursor B-cell lymphoblastic leukemia

Multiple Myeloma
Myelodysplastic Syndrome with Isolated del(5q)
Mantle cell lymphoma
Lymphoma, Follicular
Marginal Zone B-Cell Lymphoma

Dosing

Mantle cell lymphoma Single IV infusion at 2 x 10^6 CAR-positive viable T cells/kg (max 2 x 10^8 cells) following lymphodepleting chemotherapy with cyclophosphamide 500 mg/m2 IV and fludarabine 30 mg/m2 IV on each of the fifth, fourth, and third day before infusion.

Precursor B-cell lymphoblastic leukemia Single IV infusion at 1 x 10^6 CAR-positive viable T cells/kg (max 1 x 10^8 cells) following lymphodepleting chemotherapy with fludarabine 25 mg/m2 IV on days -4, -3, and -2 and cyclophosphamide 900 mg/m2 IV on day -2 before infusion.

Multiple Myeloma (combination therapy) 25 mg orally once daily on Days 1-21 of repeated 28-day cycles, in combination with dexamethasone

Multiple Myeloma (maintenance therapy following auto-HSCT) 10 mg orally once daily continuously on Days 1-28 of repeated 28-day cycles

Myelodysplastic Syndrome with Isolated del(5q) 10 mg orally once daily

Mantle cell lymphoma 25 mg orally once daily on Days 1-21 of repeated 28-day cycles

Follicular Lymphoma 20 mg orally once daily on Days 1-21 of repeated 28-day cycles for up to 12 cycles, in combination with a rituximab-product

Marginal Zone B-Cell Lymphoma 20 mg orally once daily on Days 1-21 of repeated 28-day cycles for up to 12 cycles, in combination with a rituximab-product

Contraindications

—

Pregnancy
Severe hypersensitivity to lenalidomide including angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis

Drug Interactions

26View drug interactions

1201View drug interactions

Adverse Reactions

Most common (>=20%) - MCL CRS, fever, encephalopathy, hypotension, infection with pathogen unspecified, viral infections, fatigue, tachycardias, chills, hypoxia, tremor, cough, musculoskeletal pain, nausea, edema, headache, constipation, diarrhea, decreased appetite, dyspnea, rash, insomnia, pleural effusion, aphasia, motor dysfunction

Most common (>=20%) - ALL fever, CRS, hypotension, encephalopathy, tachycardia, nausea, chills, headache, fatigue, febrile neutropenia, diarrhea, musculoskeletal pain, hypoxia, rash, edema, tremor, infection with pathogen unspecified, constipation, decreased appetite, vomiting

Serious encephalopathy, fever, infection with pathogen unspecified, CRS, hypoxia, aphasia, renal insufficiency, pleural effusion, respiratory failure, bacterial infections, dyspnea, fatigue, arrhythmia, tachycardia, viral infections

Postmarketing infusion related reaction; T cell malignancies (identified with BCMA- or CD19-directed genetically modified autologous T cell immunotherapies)

Most common (>=20%) - Multiple Myeloma combination therapy Diarrhea, anemia, constipation, peripheral edema, neutropenia, fatigue, back pain, nausea, asthenia, insomnia

Most common (>=20%) - Multiple Myeloma maintenance therapy Neutropenia, thrombocytopenia, leukopenia, anemia, upper respiratory tract infection, bronchitis, diarrhea, rash, fatigue

Most common (>=20%) - Myelodysplastic Syndromes Thrombocytopenia, neutropenia, pruritus, rash, diarrhea, constipation, nausea, nasopharyngitis, cough, dyspnea, pharyngitis, epistaxis, fatigue, pyrexia, peripheral edema, asthenia, arthralgia, back pain, muscle cramp

Most common (>=20%) - Mantle Cell Lymphoma Neutropenia, thrombocytopenia, anemia, fatigue, diarrhea, nausea, cough, dyspnea, rash, pruritus

Most common (>=20%) - Follicular and Marginal Zone Lymphoma Neutropenia, fatigue, diarrhea, constipation, nausea, cough

Serious Venous thromboembolism, arterial thromboembolism, infections including pneumonia, second primary malignancies, hepatotoxicity, severe cutaneous reactions, tumor lysis syndrome, tumor flare reactions

Postmarketing Hypothyroidism, hyperthyroidism, hepatic failure, toxic hepatitis, angioedema, anaphylaxis, acute graft-versus-host disease, viral reactivation, progressive multifocal leukoencephalopathy, pneumonitis, Stevens-Johnson Syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms

Pharmacology

CD19-directed genetically modified autologous T cell immunotherapy; binding of anti-CD19 CAR T cells to CD19-expressing target cells activates CD28 and CD3-zeta co-stimulatory signaling cascades leading to T cell activation, proliferation, acquisition of effector functions, secretion of inflammatory cytokines and chemokines, and killing of CD19-expressing cancer and normal B cells.

Lenalidomide is an immunomodulatory agent that mediates cellular activities through binding to cereblon, a component of a cullin ring E3 ubiquitin ligase enzyme complex, leading to degradation of substrate proteins and resulting in direct cytotoxic and immunomodulatory effects.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Tecartus